Although simultaneous occurrences of autoimmune pancreatitis (AIP) and cancer are occasionally observed, it remains largely unknown whether cancer and AIP occur independently or these disorders are interrelated. The aim of this study was to examine the relationship between AIP and cancer.
INTRODUCTION
Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis characterized by immunological abnormalities, including elevated serum immunoglobulin 4 (IgG4) levels and IgG4-positive lymphoplasmacytic infi ltration. In addition, AIP is associated with imaging abnormalities such as pancreatic parenchyma enlargement and pancreatic duct narrowing ( 1, 2 ) . Patients with AIP oft en exhibit IgG4-positive cell infi ltration in not only the pancreas but also in various extrapancreatic organs ( 3 ), suggesting that AIP is a manifestation of a systemic IgG4-related disease. Despite accumulating evidence of autoimmune features in this disease, however, the pathogenesis of AIP remains unknown.
Recent reports demonstrated that patients with AIP occasionally have various types of cancer, such as pancreatic cancer ( 4 -6 ) , lymphoma ( 7, 8 ) , bile duct cancer ( 9 ) , gastric cancer ( 10 ), colon cancer ( 11 ) , and thyroid cancer ( 12 ) . Yamamoto et al. ( 13 ) reported
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Masahiro Shiokawa , MD 1 that patients with IgG4-related disease are at high risk for cancer development based on an analysis of 105 patients, including 10 AIP patients. Th e precise prevalence of cancers in patients with AIP and the causal relationship between AIP and cancer, however, have not been elucidated.
In general, two mechanisms are proposed regarding co-occurrence of cancer and autoimmunity ( 14 -16 ) . First, sustained infl ammation in the presence of autoimmune disease is considered to create the immunological environments for the development of cancer, e.g., lymphomas in Sj ö gren ' s syndrome or colitic cancers in infl ammatory bowel diseases ( 17, 18 ) . In this case, the risk of cancer increases along with the duration of the underlying disease. Alternatively, cancers may induce autoimmune disease as a paraneoplastic syndrome, as represented by dermatomyositis (DM) and polymyositis (PM) ( 19 -21 ) . An important characteristic of paraneoplastic syndrome is that the risk of cancer is highest within the fi rst year aft er diagnosis of the disease ( 14, 22 ) , and clinical improvement of the disease is frequently achieved aft er successful treatment of the accompanying cancer ( 23 ) . Buchbinder et al. ( 20 ) reported that standardized incidence ratio (SIR) of cancer in the fi rst year aft er diagnosis of myositis (DM / PM) was 4.4 (95 % confidence interval (CI) 2.7 -7.1) in the population-based cohort study.
In the present study, to examine the clinicopathological association between AIP and cancer, we conducted a multicenter, retrospective cohort study. We assessed the proportion of cancer in patients with AIP, the chronological relationship between the time of AIP diagnosis and diagnosis of cancers, IgG4 expression in cancer lesions in patients with AIP, and eff ects of cancer treatment on AIP.
METHODS

Patients
AIP patients . Th e study was approved by the institutional review boards of Kyoto University Hospital and affi liated hospitals of Kyoto University. Using K861 internal coding data, which includes AIP and chronic pancreatitis, we retrospectively identifi ed 135 patients diagnosed as AIP between 2001 and 2011 at the Kyoto University Hospital or the affi liated hospitals of Kyoto University.
Patients who did not meet the Asian Criteria for AIP (see Supplementary Table 1 online) ( 24 ) were excluded from the study. All the AIP diagnosis was made at the patients ' initial visit or fi rst admission for pancreatic examination. A total of 108 patients were included in this study ( Table 1 ). According to the Asian diagnostic criteria, we diagnosed 94 AIP patients with criterion I (imaging) + II (serology), and 10 patients with criterion III (histopathology) alone in the resected pancreas, indicating the diagnosis of type I AIP ( 25 ) . All of these patients fulfi lled HISORt criteria in the United States ( 26 ) . Th e remaining four patients were diagnosed with criterion I + optional criterion (response to steroid therapy). Th ese four patients had no serology, no histology, and no extrapancreatic lesion, thus were considered to have type II AIP ( 25 ) . Th e duration of the follow-up was defi ned as the period from the date of the diagnosis of AIP until death, the most recent contact, or the study closure date (31 October 2011), whichever occurred fi rst.
Ninety-one patients (84.2 % ) received corticosteroid treatment and all these patients showed an initial response. Twelve patients (11.1 % ) were observed without corticosteroid treatment. Ten of the 12 patients had spontaneous remission, and the remaining 2 patients showed deterioration of AIP and received corticosteroid treatment. Th e remaining fi ve patients (4.6 % ) had surgical resection for suspicion of pancreatic cancer, and there was no relapse of AIP in the remaining pancreas aft er surgical resection of the AIP lesion without corticosteroid treatment. We defi ned AIP relapse as the recurrence of radiological manifestations of AIP with or without symptoms in the pancreas or extrapancreatic lesions aft er excluding other diseases ( 27, 28 ) . We expressed relapse rate of AIP by dividing the sum of AIP relapse by the follow-up period (person-years).
Gastric cancer patients without AIP . To compare gastric cancers with AIP and without AIP, we examined serum IgG4 levels in 20 gastric cancer patients without AIP, and IgG4-positive plasma cell infi ltration in 40 gastric cancer patients without AIP. We randomly selected the patients, diagnosed between 2001 and 2011 at Kyoto University Hospital, whose serum and / or tissues specimens were available.
Calculation of proportion of AIP patients with cancer and SIRs of cancer in AIP patients
We analyzed all cancers that were diagnosed concurrently with or aft er the diagnosis of AIP. We calculated the proportion of AIP patients with cancer by dividing the number of AIP patients with cancer during the follow-up period by the number of all AIP patients. Th e result is expressed as a percentage.
We calculated the SIRs of cancer in AIP patients using the national cancer rates in the population of Japan, stratifi ed by age, sex, and calendar period ( 29 ) . We calculated SIR based on the number of cancers, and each cancer was counted once, so if a patient had two malignancies, they were each counted once. Th e SIR of cancer compared the incidence of cancer observed in the AIP cohort with that expected if the cohort developed cancer at the same rate as the standard population of Japan. An SIR greater than 1 indicates an elevated incidence of cancer in the AIP patients relative to the general population of Japan.
Calculation of relative risk of cancer in AIP patients and controls
Th e control population consisted of those who fi rst had a medical checkup with the full examinations including blood examination, urine analysis, fecal occult blood, chest X-ray, abdominal ultrasonography, gastrointestinal endoscopy, and computed tomography (CT) in the lung in Kyoto Industrial Health Association. Control subjects not having AIP were matched to the cases for age ( ± 5 years) and gender with a 2:1 ratio, leading to the inclusion of 216 controls.
For calculation of relative risk of cancer, we analyzed cancers in AIP patients, which were diagnosed between 1 month before and 1 month aft er the AIP diagnosis. We analyzed cancers in controls that were diagnosed in the medical checkup.
We defi ned smoking as >10 pack-year and < 10 year since smoking cessation. We defi ned alcohol intake as >30 g alcohol per day.
Immunohistochemical study
Immunohistochemistry of the cancer lesions was performed on two representative sections from each case, using antibodies against IgG4 (clone HP6025; dilution 1:500; Serotec, Oxford, UK). Immunostaining was performed on an autoimmunostainer (Ventana XT System Benchmark; Ventana Medical Systems, Tucson, AZ ). We selected two sections in which IgG4-positive plasma cells infi ltration was most abundant, and photographed them with × 20 objective lens using a Nikon DX1200 digital camera (Nikon, Tokyo, Japan). We defi ned more than 29 cells per highpower fi eld (HPF) as " abundant " infi ltration of IgG4-positive plasma cells, between 10 and 29 cells per HPF as " moderate " infi ltration, and fewer than 10 cells per HPF as " few " infi ltration ( 30, 31 ) .
Statistical analysis
General characteristics are expressed as median and ranges. Differences concerning clinical characteristics were assessed using Student ' s t -test for continuous data, and the χ 2 -test, the Fisher ' s exact test, and multiple logistic regression analysis for categorical data. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS version 17.0, Chicago, IL). All statistical tests were two-sided. A P value of less than 0.05 was considered statistically signifi cant. Table 1 summarizes the characteristics of the AIP patients. Among the 108 patients with AIP, 18 cancers were found in 15 patients either at the same time or aft er the diagnosis of AIP during the median follow-up period of 3.3 years. Th ree patients had multiple cancers. One patient had gastric cancer and lymphoma. Another patient had gastric cancer and colon cancer, and the other patient had bile duct cancer and lung cancer. Th e proportion of AIP patients with cancer was 13.9 % (15 / 108).
RESULTS
Proportion and sites of cancers in AIP patients
Th e site of cancers in the AIP patients are shown in Table 1 . Gastric cancer was the most common. Because of the small numbers of individual cancers, we were unable to determine whether the risk for any individual type of cancer was high compared with the general population.
SIRs of cancer in AIP patients
Eighteen cancers were found in the 108 AIP patients during the overall follow-up of 415.7 person-years. Th e incidence of cancer expected from the rates of Japanese population in this cohort was 6.7. Accordingly, the SIR of cancer in the patients aft er the diagnosis of AIP was 2.7 (95 % CI 1.4 -3.9; Table 2 ). Figure 1 shows the chronological relationship between the time of diagnosis of AIP and that for cancer. Of 18 cancers, 10 were detected within the fi rst year aft er the diagnosis of AIP, including 8 cancers that were concurrently diagnosed. All the eight patients had no symptom / signs related to the cancer, and their cancers were incidentally diagnosed during the process of AIP diagnosis. Th e remaining 8 cancers were found aft er the fi rst year of AIP diagnosis. Th e SIRs of cancer in the fi rst year and in subsequent years aft er AIP diagnosis were 6.1 (CI 2.3 -9.9) and 1.5 (CI 0.3 -2.8), respectively ( Table 2 ), indicating that the occurrence of cancer was signifi cantly higher in the fi rst year. Th e cancer sites stratifi ed by time period between the diagnosis of AIP and cancer are shown in Table 2 .
Time period between the diagnosis of cancer and AIP
Relative risk of cancer at diagnosis of AIP
AIP patients underwent intensive testing, which may have enhanced the detection of cancer. Th us, it is possible that this intensive examination raised the SIR for cancer in our cohort, especially in the fi rst year. To solve this concern, we calculated the relative risk of cancer at the diagnosis of AIP in our cohort in comparison with age-and sex-matched controls who fi rst had a medical checkup with almost the same examinations as our cohort. Th e number of concurrent cancers at the diagnosis of AIP
PANCREAS AND BILIARY TRACT
Cancer in Autoimmune Pancreatitis
was eight (8 / 108) and the number of cancers in controls was three (3 / 216, P = 0.008; Table 3 ). Th e incidence of malignancy in the control group (1,388 per 100,000 people) was higher than that in the overall population of Japan (551 per 100,000 people), but comparable to that in age-and sex-matched population according to data from the National Cancer Center in Japan (1,527 per 100,000 people) ( 29 ) . Relative risk of cancer at AIP diagnosis was 4.9 (95 % CI 1.7 -14.9). In the eight AIP patients with cancer, no cancer was detected by abdominal CT or Positron Emission Tomography-CT, which were not included in the examinations in the controls. Th e diff erences of familial history of cancer, smoking, and alcohol intake between AIP patients and controls were not signifi cant.
Clinicopathological characteristics of AIP patients with cancer
Serum IgG4 levels . Serum IgG4 levels at the diagnosis of AIP were signifi cantly higher in AIP patients with cancers than in those without cancer (738 vs. 389, P = 0.02).
Extrapancreatic lesions . Extrapancreatic lesions were found in 75 of the 108 (69.4 % ) patients with AIP. Th e frequencies of sclerosing cholangitis, sclerosing sialadenitis, retroperitoneal fi brosis, renal involvement, and lung involvement were 52.8 % (57 patients), 9.3 % (10 patients), 9.3 % (10 patients), 3.7 % (4 patients), and 3.7 % (4 patients), respectively. In the 15 AIP patients with cancer, extrapancreatic lesions occurred in 11 (73.4 % ) patients. Th e frequencies of sclerosing cholangitis, sclerosing sialadenitis, retroperitoneal Lung (2) Prostate (2) Bile duct (1) Thyroid (1 Non-Hodgkin lymphoma (2) Colon (2) Lung (1) AIP, autoimmune pancreatisis; CI, confi dence interval; no., number of patients; SIR, standardized incidence ratio. The overall SIR of cancer in the patients after the diagnosis of AIP was 2.7 (95 % CI 1.4 -3.9). The SIR in the fi rst year and the subsequent years after the AIP diagnosis were 6.1 (95 % CI 2.3 -9.9) and 1.5 (95 % CI 0.3 -2.8), respectively. The site of cancers in the fi rst year and following years after the AIP diagnosis were also shown. 
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patients were successfully treated for cancer (surgery, chemotherapy, or radiotherapy), followed by corticosteroid treatment for AIP. None of the six AIP patients with abundant IgG4-positive plasma cell infi ltration around the cancers developed a relapse of AIP during the median follow-up of 4.7 years, whereas one of the two patients with few IgG4 plasma cell infi ltration relapsed during the follow-up of 0.5 and 4.4 years and relapse rate was 0.20. Sixteen of 93 AIP patients without cancer had a relapse of AIP during the median follow-up of 3.1 years and relapse rate was 0.046. As gastric cancer was the primary malignancy in our AIP patients, we examined serum IgG4 levels in 20 gastric cancer patients without AIP, and IgG4-positive plasma cell infi ltration in the surrounding tissues in 40 gastric cancer patients without AIP. We found that serum IgG4 levels were above 135 mg / dl in 5 out of 20 gastric cancer patients with a maximum level of 227 mg / dl. On the other hand, moderate IgG4-positive plasma cell infi ltration (10 to 29 / HPF) were observed in only 2 out of 40 patients, and there were no gastric cancer with abundant IgG4-positive plasma cell infi ltration (more than 29 / HPF). Th e frequency of the patients with abundant IgG4-positive plasma cells around gastric cancer was signifi cantly higher in AIP patients than non-AIP patients (2 / 3 vs. 0 / 40, P = 0.003).
DISCUSSION
Although recent studies reported cases of AIP associated with cancers ( 4 -12 ) , no studies have examined the association between AIP and cancers in a large number of patients. In the present study fi brosis, renal involvement and lung involvement were 60 % (nine patients), 13.3 % (two patients), 20.0 % (three patients), 0 and 6.7 % (one patient), respectively. In the 93 AIP patients without cancer, extrapancreatic lesions occurred in 64 (68.9 % ) patients. Th e frequencies of sclerosing cholangitis, sclerosing sialadenitis, retroperitoneal fi brosis, renal involvement, and lung involvement were 51.6 % (48 patients), 8.6 % (8 patients), 7.5 % (7 patients), 4.3 % (4 patients), and 3.2 % (3 patients), respectively. Th us, frequencies of overall extrapancreatic lesions were similar between AIP patients with and without cancer. Moreover, univariate and multi variate analyses revealed no signifi cant diff erence in the frequency of each extrapancreatic lesion between AIP patients with and without cancer. However, when we compared 8 patients concurrently diagnosed with AIP and cancer and 93 AIP patients without cancer, univariate ( P = 0.04) and multivariate analyses ( P = 0.02) revealed that frequency of retroperitoneal fi brosis was signifi cantly higher in the patients concurrently diagnosed with AIP and cancer than AIP patients without cancer (3 / 8 vs. 8 / 93).
IgG4-positive plasma cell infi ltration in the cancer lesions and relapse of AIP . Next, we evaluated IgG4-positive plasma cell infi ltration in the cancer lesions by immunohistochemistry ( Figure 2 ). To exclude the eff ect of corticosteroid therapy, we selected eight patients concurrently diagnosed with AIP and cancer, whose cancer lesions were assessed before corticosteroid treatment ( Table 4 ) . Of these eight cancer lesions, six showed abundant IgG4-positive plasma cell infi ltration in the tissues surrounding the tumor cells, whereas the other two cancer lesions had few infi ltration. All eight 
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we analyzed a relatively large number of patients, and our fi ndings demonstrated that cancer frequently occurs in patients with AIP. In a recent analysis of 105 patients with IgG4-related disease, including 10 AIP cases, Yamamoto et al. ( 13 ) reported that IgG4-related disease is a high-risk factor for cancer development. In their study, 20 % of the patients with AIP had cancers, comparable to our data. Based on the fi ndings of these two studies, patients with AIP are at high risk for cancer.
In previous reports, pancreatic cancer was the most common cancer found in patients with AIP ( 4 -6 ). In contrast, none of the patients had pancreatic cancer in the present study. Th e reason for the discrepancy between our data and previous data is unknown. One possibility is that the awareness of diff erentiating AIP from pancreatic cancer may have enhanced the publication number of pancreatic cancer with AIP in previous studies. Another possibility is that AIP associated with pancreatic cancer might not have been diagnosed as AIP in our cohort, because we usually did not sample serum and tissue IgG4 levels in typical cases with pancreatic cancer. Nevertheless, no incidence of pancreatic cancer in patients with AIP in our cohort may support the notion that the cancer development in patients with AIP does not depend directly upon underlying chronic infl ammation. In any event, patients with AIP have various type of cancers. Th e fi nding that the serum IgG4 levels were signifi cantly higher in AIP patients with cancers than in those without cancers indicates that high IgG4 might be a useful marker for concurrent cancers.
Th e reason for the high risk of cancer in patients with AIP is unknown at present. In the present study, cancer tissues in AIP patients that were examined histologically before the administration of corticosteroids were frequently infi ltrated with IgG4-positive plasma cells. Th is fi nding may suggest that the cancers in patients with AIP arise in the background of IgG4-related infl ammation. It is well known that chronic infl ammation has an important role in the development of various types of cancer, including Helicobacter pylori -induced gastric cancer, hepatitis C virus-related hepatocellular carcinoma, and colitic cancer ( 17, 18, 32, 33 ) . However, it should be noted in our study that no AIP patient developed cancer in the pancreas, a major site of infl ammation. Th is fact seems to contradict to an idea that chronic infl ammation due to AIP is responsible for the development of cancer. In this context, it is worth noting that the risk of cancer development was the highest in the fi rst year of AIP diagnosis in our study. Moreover, seven of eight patients, in whom cancer was histologically diagnosed before corticosteroid administration, did not have a recurrence of AIP aft er successful cancer treatment. In addition, curative cancer treatment prevented the relapse of AIP in the six patients whose cancer tissue showed abundant IgG4-positive plasma cell infi ltration. Taken together, the data may indicate that the existing cancers have some roles in the development of AIP, raising an idea that AIP is a manifestation as a paraneoplastic syndrome in some patients. Th e fact that the relative risk of cancer at AIP diagnosis was signifi cantly high in comparison with age-and sex-matched control subjects who received similar levels of examinations may further support an idea that certain portion of AIP is categorized as paraneoplastic syndrome.
Another well-known paraneoplastic syndrome that has an autoimmune nature is DM / PM ( 14 -16 ) . In patients with DM and PM, the SIR for cancers ranges from 3.7 to 8.8 and 1.7 to 2.2, respectively ( 20, 21 ) . AIP and PM / DM share several clinical fi ndings as paraneoplastic syndrome. For instance, in our cohort with 108 patients, cancer was diagnosed concomitantly with AIP or within the fi rst year aft er the AIP diagnosis in eight and two patients, respectively. Th us, similar to the previous reports on PM / DM ( 14, 22 ) , the risk for cancer diagnosis is highest within the fi rst year aft er diagnosis of AIP, including the time of diagnosis of AIP. Notably, the cancers concurrently diagnosed with AIP were not detected by abdominal CT or Positron Emission Tomography-CT, which were not included in the examinations in the controls, excluding the possibility that the higher level of diagnostic work-up in AIP patients increased the probability of cancer diagnosis in our cohort. In addition, clinical and immunological abnormalities seen in both AIP and DM / PM are improved aft er successful treatment of the cancers ( 34 ) . Th ese similarities between DM / PM and AIP with regard to the relationship between cancer in the fi rst year aft er AIP diagnosis. Moreover, to solve this concern, we calculated the relative risk of cancer in comparison with age-and sex-matched control people who fi rst had a medical checkup with almost the same examinations as our cohort. In additional limitation, the sample size was relatively small and retrospective studies are more prone to bias than prospective studies, and this may have contributed to the higher SIR and relative risk. A prospective study with a large number of patients should be performed.
In conclusion, patients who fulfi lled the accepted criteria for AIP are at high risk for having cancer. Th e highest risk for cancer is in the fi rst year aft er AIP diagnosis, including the time at the diagnosis of AIP, and there is a very low relapse rate of AIP aft er successful treatment of the accompanying cancer. Th ese data might indicate that a certain portion of AIPs can be categorized as a paraneoplastic syndrome. Finally, more studies are needed to determine whether screening for neoplasia should be done in patients with AIP, and also to decide whether high prevalence of cancer in our cohort really refl ects its paraneoplastic phenomenon or merely an epiphenomenon.
